Chest ACCP Member Benefits
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O’Riordan, T. G.
Right arrow Articles by Chen, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O’Riordan, T. G.
Right arrow Articles by Chen, J. J.
(Chest. 2006;129:124-132.)
© 2006 American College of Chest Physicians

Assessing the Effects of Racemic and Single-Enantiomer Albuterol on Airway Secretions in Long-term Intubated Patients*

Thomas G. O’Riordan, MD; Wenyang Mao, MS; Lucy B. Palmer, MD and John J. Chen, PhD

* From the Division of Pulmonary/Critical Care, Department of Medicine and Department of Preventive Medicine, Stony Brook University, Stony Brook, NY.

Correspondence to: Thomas G. O’Riordan, MD, Division of Pulmonary/Critical Care Medicine, HSC 17–040, Stony Brook University, Stony Brook, NY 11794-8172; e-mail: toriordan{at}notes.cc.sunysb.edu

Abstract

Objective: In vitro data suggest that the S-enantiomer of albuterol can induce mucociliary dysfunction. This clinical study assesses the clinical significance of standard doses of the S-enantiomer on airway secretions in long-term intubated patients by comparing a racemic formulation of albuterol, an R-enantiomer formulation, and normal saline solution.

Design: A placebo-controlled crossover study.

Patients: Fourteen stable intubated patients with a median duration of intubation of 21 months and a median age of 72 years.

Setting: Long-term ventilator unit in skilled nursing facility.

Interventions: Following a 2-week washout period during which regularly scheduled ß2-agonists were discontinued, tracheal aspirates were collected for 4 h/d for a 5-day period to establish baseline values, and the patients were then randomized in crossover manner to each of three nebulized treatments: normal saline solution, racemic albuterol, and R-albuterol. Each treatment was administered three times daily for 5 days, followed by a 2-day washout.

Measurements: Tracheal aspirates were analyzed for volume, sodium, chloride, bicarbonate, interleukin (IL)-8, IL-1ß, soluble intercellular adhesion molecule, and tumor necrosis factor-{alpha}.

Results: There were no consistent significant differences among the three treatment periods either in terms of volume of secretions or in the concentrations of the electrolytes or the inflammatory indexes. However, all three treatments, including saline solution, were associated with increased secretion volume after the first dose, but this effect was not apparent on subsequent doses.

Conclusion: There were no significant differences between racemic albuterol and R-albuterol observed in this study for any of the parameters studied, suggesting that the S-enantiomer does not adversely affect airway secretions at recommended doses. In addition, the routine administration of nebulized ß2-sympathomimetic agonists to stable patients undergoing prolonged intubation, for the sole purpose of changing the volume and composition of secretions of airway secretions, is not supported by the results of this study.

Key Words: albuterol • ß2-agonists • hypersecretion • levalbuterol • tracheobronchitis







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Chest Physicians.